2016 Annual Meeting of the American Association for the Study of Liver Diseases*

Listen to a rapid review of the key hepatology studies from Boston 2016 expected to affect clinical practice, followed by expert answers to participants’ questions.

In this Expert Analysis, Ira M. Jacobson, MD, and Stefan Zeuzem, MD, provide expert interpretation of the most clinically important new data on HCV, HBV, and NASH from this important annual conference.

Ira M. Jacobson, MD Stefan Zeuzem, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Released: February 1, 2017 Expired: No longer available for credit

In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.

The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.

Mark S. Sulkowski, MD Released: January 31, 2017

The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.

Brent A. Neuschwander-Tetri, MD Released: March 10, 2017